Sofinnova Investments related stories
All articles and analysis
Trice Medical pulls in $6.5 mlnTrice Medical has received an additional $6.5 million in Series B financing, raising the total round to $18.1 million. HealthQuest Capital was the lead investor of the extension. Other backers included Safeguard Scientifics Inc and BioStar Ventures. Based in King of Prussia, Pennsylvania, Trice Medical is a provider of private diagnostics solutions focused on micro-invasive technologies.
- VC-backed Ascendis Pharma goes public
Danish biotech firm Ascendis Pharma has raised $108 million for its IPO after pricing its 6 million shares at $18 per share. The stock begins trading Wednesday on the NASDAQ under the ticker symbol "ASND." BofA Merrill Lynch and Leerink Partners are serving as the lead underwriters. Ascendis Pharma's backers include Sofinnova Ventures, OrbiMed, Vivo Capital, Venrock, RA Capital Management and Janus Capital Management.
- Sofinnova Ventures taps former InterMune CEO as executive partner
Sofinnova Ventures has hired Daniel G. Welch as an executive partner. Welch is the former CEO, president and chairman of InterMune.
VC-backed gene therapy firm Spark Therapeutics files for IPOPhiladelphia-based Spark Therapeutics, a developer of gene therapy products that treat rare, debilitating diseases, has filed for an IPO.
- VC-backed Histogenics goes public
Waltham, Mass.-based Histogenics Corp., a regenerative medicine developer, has debuted its IPO after pricing its 5.9 million shares at $11 per share. The stock began trading Wednesday on the NASDAQ under the ticker symbol "HSGX." Cowen and Co., Needham & Co. and Canaccord Genuity are the lead underwriters. Histogenics' backers include Sofinnova Ventures, Split Rock Partners and Altima Partners.
- Deerfield leads $42.5 mln round for Audentes
San Francisco-based biotech firm Audentes Therapeutics has secured $42.5 million in Series B financing. Deerfield Management led the round with participation from Sofinnova Ventures, Venrock, OrbiMed, 5AM Ventures and Versant Ventures. As a result of the transaction, Jonathan Leff, a partner at Deerfield, will join Audentes' board of directors.
- Sofinnova Ventures, OrbiMed, Vivo Capital lead $60 mln funding in Ascendis Pharma
Sofinnova Ventures, OrbiMed and Vivo Capital have led a $60 million Series D funding in Ascendis Pharma, a biotechnology company. Other investors in the funding include Janus Capital Management, Venrock, RA Capital Management, Rock Springs Capital and Sectoral Asset Management. Ascendis Pharma's largest shareholder, Sofinnova Partners, also participated in the funding round. James Healy of Sofinnova Ventures, Jonathan Silverstein of OrbiMed and Albert Cha of Vivo Capital have joined the company's board of directors.
- Aclaris attracts $21 mln Series B
Aclaris Therapeutics said Thursday that it has received $21 million in Series B financing. The investors were return backers Vivo Ventures, Fidelity Biosciences and Sofinnova Ventures. Based in Malvern, Penn., Aclaris Therapeutics is a specialty pharmaceutical firm focused on developing a treatment that removes various skin lesions.
IPO Profile: Auris Medical Holding AGInvestors include Sofinnova Ventures and Idinvest Partners